InsiderTrades.com logo

SLRX Insider Trading

Insider Ownership Percentage: 0.30%
Insider Buying (Last 12 Months): $19,750.00
Insider Selling (Last 12 Months): $0.00

Salarius Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Salarius Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Salarius Pharmaceuticals Share Price & Price History

Current Price: $0.87
Price Change: ▲ Price Increase of +0.011 (1.28%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for SLRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Salarius Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2025Arnold C HanishDirectorBuy5,000$0.75$3,750.005,015View SEC Filing Icon  
11/20/2025Mark J RosenblumCFOBuy20,000$0.80$16,000.0020,177View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Salarius Pharmaceuticals (NASDAQ:SLRX)

11.88% of Salarius Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SLRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Salarius Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2024Armistice Capital LLC22,750$54K0.0%-72.9%3.811%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC88,000$57K0.0%-60.9%2.234%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC225,000$0.15M0.0%+105.2%5.711%Search for SEC Filing on Google Icon
11/15/2021HighTower Advisors LLC26,000$26K0.0%N/A0.058%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.116,309$0.12M0.0%-13.7%0.260%Search for SEC Filing on Google Icon
8/16/2021State Street Corp142,552$0.15M0.0%N/A0.318%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp65,022$69K0.0%+25.9%0.145%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Salarius Pharmaceuticals logo
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
Read More on Salarius Pharmaceuticals

Today's Range

Now: $0.87
Low: $0.83
High: $0.92

50 Day Range

MA: $2.75
Low: $0.75
High: $4.60

52 Week Range

Now: $0.87
Low: $0.71
High: $108.00

Volume

573,511 shs

Average Volume

5,143,067 shs

Market Capitalization

$5.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Who are the company insiders with the largest holdings of Salarius Pharmaceuticals?

Salarius Pharmaceuticals' top insider investors include:
  1. Mark J Rosenblum (CFO)
  2. Arnold C Hanish (Director)
Learn More about top insider investors at Salarius Pharmaceuticals.